PRESCRIPTION DRUG IMPORT ACT
HB1272 creates the Wholesale Prescription Drug Importation Program Act and directs the Illinois Department of Public Health to establish a state-run program to import certain prescription drugs, primarily from Canadian suppliers, for resale in Illinois at lower cost. The program is designed to contract with licensed prescription drug wholesalers and Canadian manufacturers, distributors, or pharmacies, and to make imported drugs available through registered health benefit plan issuers, health care providers, and pharmacies. The Department would also publish a list of eligible drugs and prices, operate an outreach and information system, and adopt rules to administer the program.
The bill limits the program to drugs that meet federal safety and importation requirements, generate expected consumer savings, and are not excluded categories such as controlled substances, biological products, infused drugs, intravenously injected drugs, drugs inhaled during surgery, or parenteral drugs. It also requires compliance with federal tracking, tracing, verification, and identification rules, prohibits resale outside Illinois, and allows the Department to expand the program to other countries if federal law permits. The Department must monitor anticompetitive behavior, conduct audits of participating wholesalers, and provide annual reports on participation, savings, and implementation.
If enacted, HB1272 would create a new state program and administrative framework within the Department of Public Health, adding new duties related to contracting, registration, pricing publication, compliance monitoring, auditing, and reporting. It would affect prescription drug wholesalers, Canadian suppliers, pharmacies, health care providers, and health benefit plan issuers by creating a pathway to import and dispense qualifying drugs under state oversight. The bill also contemplates program funding through appropriations, fees on drugs sold through the program, or another funding mechanism, and it conditions implementation on any necessary federal waiver or authorization.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall sentiment appears to be policy-driven and cost-savings oriented rather than overtly contentious in the available record. The measure is framed as a consumer affordability initiative aimed at lowering prescription drug costs for Illinois residents. Because no transcripts or vote history are provided, there is no documented support or opposition to characterize beyond the bill’s stated purpose.
The main points of potential contention are likely to be federal preemption and regulatory compliance, since the bill expressly requires adherence to federal importation, tracking, and verification rules and allows delays until any needed federal waiver or authorization is obtained. Another likely issue is drug safety and supply-chain integrity, given the reliance on imported drugs and the need to ensure FDA standards are met. Stakeholders that may scrutinize the bill include domestic drug manufacturers, wholesalers, pharmacies, insurers, and consumer advocates, with possible debate over whether importation will meaningfully reduce costs without creating legal or operational risks.